Bottom line
RSPH vs FHLC: the short answer
RSPH (Invesco S&P 500 Equal Weight Health Care ETF) and FHLC (Fidelity MSCI Health Care Index ETF) are both etfs.
But FHLC is far broader, holding 337 positions to 63 for RSPH, so beyond the top names it adds exposure RSPH doesn't have.
FHLC is cheaper at 0.084% vs 0.4% — a difference of $32 a year per $10,000 invested.
Over five years, FHLC returned +7.2% a year vs +4.7% for RSPH (reporting dates differ).
Updated Nov 19, 2026
RSPH vs FHLC side by side
| RSPH | FHLC | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Invesco | Fidelity |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.4% | 0.084% |
| Annual cost per $10k | $40 | $8.4 |
| 10-yr cost on $10k (prospectus) | $505 | $108 |
| Max front load | None | None |
| 12b-1 fee | — | 0% |
| 1-yr return | +9.3% | +2.6% |
| 5-yr return (annualized) | +4.7% | +7.2% |
| 10-yr return (annualized) | +8.2% | +8.8% |
| Best quarter | +17.5% | +16.4% |
| Worst quarter | −14.3% | −13.1% |
| Net assets (fund) | $766.9M | $3.3B |
| Number of holdings | 63 | 337 |
| Portfolio turnover | 24% | 3% |
| Returns as of | Dec 31, 2025 | Nov 30, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RSPH | FHLC | Difference |
|---|---|---|---|
| 2024 | −0.8% | +2.6% | −3.4% |
| 2023 | +3.9% | +2.5% | +1.5% |
| 2022 | −9.2% | −5.5% | −3.8% |
| 2021 | +23.0% | +20.4% | +2.7% |
| 2020 | +18.9% | +18.1% | +0.8% |
| 2019 | +25.3% | +21.9% | +3.4% |
| 2018 | −0.3% | +5.5% | −5.8% |
| 2017 | +23.4% | +23.3% | +0.1% |
| 2016 | −4.5% | −3.3% | −1.2% |
| 2015 | +8.2% | +7.0% | +1.2% |
Source: Fund prospectus bar charts
Holdings overlap
7 of RSPH's top 25 holdings also appear in FHLC's top 25.
| Holding | RSPH | FHLC |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 1.96% | 1.15% |
| Thermo Fisher Scientific Inc. | 1.84% | 3.09% |
| Abbott Laboratories | 1.83% | 2.66% |
| Bristol-Myers Squibb Co. | 1.82% | 1.93% |
| Amgen Inc. | 1.77% | 3.00% |
| AbbVie Inc. | 1.73% | 6.42% |
| Cencora, Inc. | 1.71% | 0.83% |
Source: SEC Form N-PORT
RSPH top 10
- Bio-Techne Corp. — 2.13%
- IQVIA Holdings Inc. — 2.00%
- Baxter International Inc. — 1.99%
- Regeneron Pharmaceuticals, Inc. — 1.96%
- Mettler-Toledo International Inc. — 1.94%
- Charles River Laboratories International, Inc. — 1.93%
- Veeva Systems Inc. — 1.93%
- DaVita Inc. — 1.87%
- Moderna, Inc. — 1.85%
- Thermo Fisher Scientific Inc. — 1.84%
FHLC top 10
- Eli Lilly & Co — 13.35%
- Johnson & Johnson — 8.93%
- AbbVie Inc — 6.42%
- UnitedHealth Group Inc — 5.44%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 3.09%
- Amgen Inc — 3.00%
- Abbott Laboratories — 2.66%
- Gilead Sciences Inc — 2.34%
- Pfizer Inc — 2.06%
FAQ
What is the difference between RSPH and FHLC?
Which is cheaper, RSPH or FHLC?
Should I own both RSPH and FHLC?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.